Psomagen is a US-based genomics company, spun off from Macrogen, providing comprehensive genomic sequencing and bioinformatics services. They cater to the research, academic, pharmaceutical, and clinical sectors with services including next-generation sequencing (NGS), Sanger sequencing, CES services, and bioinformatics analysis. Psomagen operates CLIA-certified and CAP-accredited laboratories, emphasizing high-quality data and tailored solutions for diverse applications like genetic research, drug discovery, and diagnostics. They aim to advance precision medicine and life sciences through cutting-edge genomic technologies and expertise.
Serves as the main operational hub, housing corporate leadership, research and development, CLIA-certified and CAP-accredited sequencing laboratories, and customer support.
State-of-the-art laboratory facilities equipped for high-throughput sequencing and advanced bioinformatics. Located within the I-270 Technology Corridor, a prominent biotech hub.
A scientifically driven and innovative environment, focusing on precision, quality, and collaboration to meet the complex needs of its diverse clientele in the life sciences.
Strategically located near key federal research institutions like the NIH and FDA, fostering collaborations and serving the dense biotech ecosystem of the Mid-Atlantic region.
While Psomagen's direct offices are primarily in the United States, it operates as a key part of Macrogen's global network. This connection allows Psomagen to offer its services internationally and leverage global R&D, high-throughput sequencing capabilities, and bioinformatics expertise, particularly from Macrogen's extensive facilities in South Korea and other worldwide locations. This enables support for multi-national research projects and clients across North America, Europe, and Asia.
1330 Piccard Drive
Rockville
MD
USA
Address: One Broadway, 14th Floor, Cambridge, MA 02142
To provide localized support and foster collaborations within the New England life sciences cluster, one of the world's leading centers for biomedical innovation.
Address: 135 W 41st St, New York, NY 10036
Supports business growth and client engagement in the New York region, leveraging proximity to financial institutions and research centers.
Address: 6199 Cornerstone Ct. E, Ste 101, San Diego, CA 92121
To serve the significant life sciences market on the West Coast, offering accessible genomic services and fostering regional partnerships.
Address: 10F, 1001, World Cup Buk-ro 396, Sangam-dong, Mapo-gu, Seoul, Republic of Korea 03925
Serves as the global R&D and operational backbone, supporting Psomagen with large-scale capabilities and technological advancements originating from the parent company.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Psomagen' leadership includes:
Psomagen has been backed by several prominent investors over the years, including:
Psomagen completed its merger with a subsidiary of its parent company, Macrogen, and became a private company in January 2024. Specific executive changes related to this transition, if any beyond the existing team leading through the merger, have not been widely publicized. The core leadership team appears to have remained consistent through this period.
Discover the tools Psomagen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Psomagen likely utilizes common corporate email formats. Based on publicly available information and standard practices, emails typically combine an employee's first name (or initial) and last name.
Common formats include [first].[last]@psomagen.com or [first_initial][last]@psomagen.com.
Format
ryan.kim@psomagen.com
Example
80%
Success rate
GlobeNewswire • January 29, 2024
Psomagen, Inc. today announced the successful completion of its previously announced merger with an indirect, wholly-owned subsidiary of Macrogen, Inc. As a result of the merger, Psomagen has become a private company and its common stock has ceased trading on the Nasdaq Capital Market....more
GlobeNewswire • January 25, 2024
Psomagen, Inc. announced the pricing of its underwritten public offering of 3,478,261 shares of its common stock at a public offering price of $2.30 per share, for gross proceeds of approximately $8.0 million, prior to its merger and delisting....more
GlobeNewswire • September 6, 2023
Psomagen, Inc. announced that its CEO, Ryan W. Kim, and CFO, JC Lee, would present at the H.C. Wainwright 25th Annual Global Investment Conference held in September 2023, discussing the company's strategy and services....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Psomagen, are just a search away.